{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

InvestorNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Completes Manufacturing Readiness for Wellness Product Launch

July 23, 2026 — BioAdaptives (OTC: BDPT) a developer of science-driven wellness products, announced it has completed commercial manufacturing and logistics supply chain readiness, positioning the company to begin rolling out its next-generation wellness platforms next month. The company said it spent the past quarter securing standardized raw materials and partnering with GMP-compliant manufacturing facilities to support anticipated demand for its MyndSystem(TM) cognitive performance platform and upcoming Xcellara(TM) cellular wellness products.

420 with CNW — Senate Democrats Introduce Bill to Legalize Marijuana Federally

July 22, 2026 — A group of Senate Democrats has renewed its push to remove marijuana from the federal list of controlled substances, taking a broader approach than the Trump administration’s ongoing effort to reclassify marijuana as a Schedule III drug. Whether or not this latest effort succeeds in changing the federal status of marijuana remains to be seen, and businesses like Tilray Brands Inc.

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Preclinical Data Supporting IV Cancer Therapy

July 22, 2026 — Oncotelic Therapeutics (OTCQB: OTLC) ogether with Sapu Nano, announced publication of a peer-reviewed study in Biomedicines detailing the preclinical data supporting Sapu003, its intravenous Deciparticle(TM) formulation of everolimus. The publication outlines the program’s absorption, distribution, metabolism, excretion (“ADME”), pharmacokinetics, tissue distribution, GLP toxicology and cGMP manufacturing data, supporting the ongoing Phase 1 clinical evaluation of Sapu003 in patients with advanced solid tumors.

InvestorNewsBreaks – Olenox Industries (NASDAQ: OLOX) Outlines Integrated Energy, AI Strategy in Shareholder Letter

July 22, 2026 — Olenox Industries (NASDAQ: OLOX) issued a shareholder letter from Chairman and CEO Mike McLaren outlining the company’s strategy to integrate natural gas production, electricity generation and AI-driven computing into a vertically integrated energy platform. McLaren said Olenox aims to capture greater value by converting its natural gas into electricity and directing that power toward its highest-value applications, including AI workloads, bitcoin mining, data infrastructure or grid sales during peak pricing periods, rather than relying solely on commodity wellhead pricing.

Dietary Fat Balance Could Influence Immune System Function, Study Finds

July 22, 2026 — A new study suggests that theratio of two common dietary fats may profoundly influence how well your immune system fights infection and cancer. Specifically, the balance between polyunsaturated and monounsaturated fats could alter the composition of immune cell membranes, making the cells more vulnerable to a destructive process called ferroptosis.

TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer

July 22, 2026 — Kairos Pharma (NYSE American: KAPA) has entered into a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO(R) (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer involving bone. ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance and is currently being evaluated in Phase 1 and Phase 2 clinical trials.

InvestorNewsBreaks – American Fusion Inc. (OTC: AMFN) Appoints Chief Revenue Officer to Lead Commercial Strategy

July 22, 2026 — American Fusion (OTC: AMFN) has appointed Alec Rossa as chief revenue officer, tasking the longtime executive with leading the company’s global commercial strategy as it advances development of its proprietary Texatron(TM) Fusion Engine(TM). Rossa will oversee customer development, strategic partnerships, government and institutional relationships and commercialization of the company’s planned Power-as-a-Service (“PaaS”) business model.